Structural probing of off-target G protein-coupled receptor activities within a series of adenosine/adenine congeners

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Paoletta, Silvia ^a   Tosh, Dilip K ^a   Salvemini, Daniela ^b   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE DERIVATIVE; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR; NUCLEOSIDE; SEROTONIN RECEPTOR; ADENINE; ADENOSINE; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG STRUCTURE; DRUG TARGETING; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; PROTEIN CONFORMATION;

ADENINE; ADENOSINE; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901425446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097858     Document Type: Article

References (40)

1. Huggins DJ, Sherman W, Tidor B (2012) Rational approaches to improving selectivity in drug design. J Med Chem 55: 1424-1444.
2. Peters JU, Hert J, Bissantz C, Hillebrecht A, Gerebtzoff G, et al. (2012) Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discov Today 17: 325-335.
3. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. Nature 462: 175-181.
4. Peprah K, Zhu XY, Eyunni SV, Setola V, Roth BL, et al. (2012) Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents. Bioorg Med Chem 20: 1291-1297.
5. Triggle D (2003) 1,4-Dihydropyridines as Calcium Channel Ligands and Privileged Structures. Cell Mol Neurobiol 23: 293-303.
6. Katritch V, Cherezov V, Stevens RC (2013) Structure-Function of the G Protein-Coupled Receptor Superfamily. Annu Rev Pharmacol Toxicol 53: 531-556.
7. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller C (2011) Nomenclature and classification of adenosine receptors - An update. Pharmacol Rev 63: 1-34.
8. 3-selective adenosine agonists. J Med Chem 37: 636-646.
9. 3AR) agonists. Drug Disc Today 17: 359-366.
10. 2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58: 613-623.
11. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, et al. (2013) Molecular signatures of G-protein-coupled receptors. Nature 494: 185-194.
12. Dimova D, Hu Y, Bajorath J (2012) Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity. J Med Chem 55: 10220-10228.
13. Jensen NH, Roth BL (2008) Massively parallel screening of the receptorome. Comb Chem High Throughput Screen 11: 420-426. (Pubitemid 351969359)
14. Chen JF, Eltzschig HK, Fredholm BB (2013) Adenosine receptors as drug targets - what are the challenges? Nature Rev Drug Disc 12: 265-286.
15. 3 adenosine receptor activation. FASEB J 26: 1855-1865.
16. 3 adenosine receptor-selective nucleosides: Combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem 55: 4847-4860.
17. 1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: Receptor docking and potent anticonvulsant activity. J Med Chem 55: 8075-8090.
18. 3 adenosine receptor ligands: Combined 2-arylethynyl and bicyclohexane substitutions. ACS Med Chem Lett 3: 596-601.
19. 3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem 16: 8546-8556.
20. Klotz KN, Kachler S, Lambertucci C, Vittori S, Volpini R, et al. (2003) 9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities. Naunyn Schmiedebergs Arch Pharmacol 367: 629-634 (Pubitemid 36829462)
21. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, et al. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330: 1091-1095.
22. Wang C, Jiang Y, Ma J, Wu H, Wacker D, et al. (2013) Structural basis for molecular recognition at serotonin receptors. Science 340: 610-614.
23. Warne T, Edwards PC, Leslie AG, Tate CG (2012) Crystal structures of a stabilized b1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 20: 841-849.
24. Ballesteros J A, Weinstein H (1995) Integrated methods for the construction of three-dimensional models of structure 2function relations in G protein-coupled receptors. Methods Neurosci 25: 366-428.
25. Wacker D, Wang C, Katritch V, Han GW, Huang XP, et al. (2013) Structural features for functional selectivity at serotonin receptors. Science 340: 615-619.
26. 2A adenosine receptor. Science 332: 322-327.
27. Allen JA, Roth BL (2011) Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 51: 117-144.
28. Costanzi S, Ivanov AA, Tikhonova IG, Jacobson KA (2007) Structure and Function of G Protein-Coupled Receptors Studied Using Sequence Analysis, Molecular Modeling and Receptor Engineering: Adenosine Receptors. Front Drug Des Discovery 3: 63-79.
29. 2A Adenosine Receptors and Biogenic Amine G Protein-Coupled Receptors. J Med Chem 40: 2588-2595.
30. Lin H, Sassano MF, Roth BL, Shoichet BK (2013) A pharmacological organization of G protein-coupled receptors. Nat Methods 10: 140-146.
31. 1 adenosine receptor antagonists. PLoS One 7: e49910.
32. Haupt VJ, Daminelli S, Schroeder M (2013) Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key. PLoS One 8: e65894.
33. 3 Adenosine Receptors. Mol Pharmacol 80: 458-465.
34. Hopkins AL, Mason JS, Overington JP (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16: 127-136. (Pubitemid 43221881)
35. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al.(2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242 (Pubitemid 30047768)
36. The UniProt Consortium (2012) Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 40: D71-D75.
37. Molecular Operating Environment (MOE), version 2011.10, Chemical Computing Group Inc., 1255 University St., Suite 1600, Montreal, QC, H3B 3X3 (Canada)
38. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749. (Pubitemid 38380917)
39. Schrödinger Suite 2012; Schrödinger, LLC: New York, NY.
40. Halgren T (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49: 377-389.